• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Lebanon Pharmaceuticals and Healthcare Report Q1 2013 - Product Image

Lebanon Pharmaceuticals and Healthcare Report Q1 2013

  • ID: 2373251
  • January 2013
  • Region: Lebanon
  • 95 pages
  • Business Monitor International

FEATURED COMPANIES

  • Abbott Laboratories
  • Algorithm
  • Company Profiles
  • Indigenous Companies
  • Merck & Co
  • Novartis
  • MORE

BMI View:

Although this quarter has seen a number of regulatory initiatives taken by the Lebanese Minister of Health, Ali Hassan Khalil, to improve the state of the pharmaceutical industry, we maintain that a multilateral approach is required to improve foreign direct investment (FDI) into the country and that, in the short to medium term, investment will be deterred and medical tourism revenue diminished by wider macroeconomic and political vulnerabilities. Nonetheless, BMI holds to the view that the country provides stable opportunities for multinationals to tap into the cultural prioritisation for medicines and benefit from the increasingly-urbanized population, although risks include a relatively weak regulatory framework, poor intellectual property laws and medicine pricing restrictions.

Headline Expenditure Projections

- Pharmaceuticals: LBP1,959bn (US$1.30bn) in 2011 to LBP2,061bn (US$1.37bn) in 2012;
+8.6% in local currency terms and +9.2% in US dollar terms. Forecast revised upwards from Q412 due to modifications to historical figures.

- Healthcare: LBP4,495bn (US$2.99bn) in 2011 to LBP4,750bn (US$3.15bn) in 2012; +5.7% in local currency terms READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Algorithm
  • Company Profiles
  • Indigenous Companies
  • Merck & Co
  • Novartis
  • MORE

Executive Summary 5

SWOT Analysis 7

Lebanon Pharmaceuticals And Healthcare Industry SWOT 7

Lebanon Political SWOT 8

Lebanon Economic SWOT 8

Lebanon Business Environment SWOT 9

Pharmaceutical Risk / Reward Ratings 10
Table: Middle East And Africa (MEA) - Regional Pharmaceutical Risk Reward Ratings for Q113 10

Rewards 12

Risks 12

Lebanon - Market Summary 14

Regulatory Regime 15

Regulatory Developments 16

Counterfeit Drugs 17

Public Sector Procurement 17

Intellectual Property Regime 18

Free Trade Agreements 21

Pricing Regime 21

Reimbursement Regime 23

Industry Developments 24

Epidemiology 24

Non-Communicable Diseases 25

HIV/AIDS Infections 26

Healthcare Sector 26

Hospital Sector 27

Healthcare Insurance 28

Health Insurance Reform 29

Medical Tourism 32

Regional Healthcare Collaboration 33

Clinical Trials 33

Medical Devices 34

Industry Forecast Scenario 35

Overall Market Forecast 35
Table: Lebanon Pharmaceutical Sales, Historical Data and Forecasts 36

Healthcare Market Forecast 38
Table: Lebanon Healthcare Expenditure Trends, Historical Data and Forecasts 39
Table: Lebanon Government Healthcare Expenditure Trends, Historical Data and Forecasts 39
Table: Lebanon Private Healthcare Expenditure Trends, Historical Data and Forecasts 39

Key Growth Factors - Macroeconomic 41

Prescription Drug Market Forecast 48
Table: Lebanon Prescription Drug Market Indicators, Historical Data and Forecasts 48

Patented Drug Market Forecast 50
Table: Lebanon Patented Drug Market Indicators, Historical Data and Forecasts 51

Generic Drug Market Forecast 52
Table: Lebanon Generics Drug Market Indicators, Historical Data and Forecasts 54

OTC Medicine Market Forecast 55
Table: Lebanon Over-The-Counter (OTC) Medicine Market Indicators, Historical Data and Forecasts 56

Pharmaceutical Trade Forecast 57
Table: Lebanon Pharmaceutical Trade Data And Forecasts (US$mn) 59
Table: Lebanon Pharmaceutical Trade Data And Forecasts (LBPmn) 59

Medical Device Market Forecast 60
Table: Lebanon Medical Device Market Indicators, Historical Data and Forecasts 60

Other Healthcare Data Forecasts 62

Key Risks to BMI Forecasts 63

Competitive Landscape 64

Pharmaceuticals Sector 64

Recent Pharmaceuticals Sector Developments 65

Pharmaceutical Distribution 65

Retail Pharmacy Sector 66

Company Profiles 67

Indigenous Companies 67

Benta Pharmaceutical Industries (BPI) 67

Pharmaline 69

Chalhoub Pharmaceuticals (CHAPHA) 71

Alfa Laboratories 72

Algorithm 73

Codipha 75

Multinational Companies 76

Pfizer 76

Novartis 77

Merck & Co 78

Johnson & Johnson (J&J) 79

Sanofi 80

GlaxoSmithKline 82

Abbott Laboratories 84

Demographic Outlook 85

Lebanon's Population By Age Group, 1990-2020 ('000) 85

Lebanon's Population By Age Group, 1990-2020 (% of total) 86

Lebanon's Key Population Ratios, 1990-2020 87

Lebanon's Rural And Urban Population, 1990-2020 87

Glossary 88

BMI Methodology 90

How We Generate Our Pharmaceutical Industry Forecasts 90

Pharmaceuticals Business Environment Ratings 91

Risk/Reward Ratings Methodology 91

Ratings Overview 91
Table: Pharmaceutical Business Environment Indicators 92

Weighting 93
Table: Weighting Of Components 93

Sources 93
Table: Exports and Imports Indicators 2008-2016 93

Note: Product cover images may vary from those shown

Company Profiles
Indigenous Companies
Benta Pharmaceutical Industries (BPI)
Pharmaline
Chalhoub Pharmaceuticals (CHAPHA)
Alfa Laboratories
Algorithm
Codipha
Multinational Companies
Pfizer
Novartis
Merck & Co
Johnson & Johnson (J&J)
Sanofi
GlaxoSmithKline
Abbott Laboratories

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos